Projection of power and events in clinical trials with a time-to-event outcome

被引:5
|
作者
Royston, Patrick [1 ,2 ]
Barthel, Friederike M-S [3 ]
机构
[1] Hub Trials Methodol Res, MRC Clin Trials Unit, London, England
[2] UCL, London, England
[3] GlaxoSmithKline Inc, Oncol Res & Dev, Uxbridge, Middx, England
来源
STATA JOURNAL | 2010年 / 10卷 / 03期
基金
英国医学研究理事会;
关键词
st0013_2; artpep; artbin; artsurv; artmenu; randomized controlled trial; time-to-event outcome; power; number of events; projection; ARTPEP; ART; SAMPLE-SIZE; SURVIVAL;
D O I
10.1177/1536867X1001000306
中图分类号
O1 [数学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 0701 ; 070101 ;
摘要
In 2005, Barthel, Royston, and Babiker presented a menu-driven Stata program under the generic name of ART (assessment of resources for trials) to calculate sample size and power for complex clinical trial designs with a time-to-event or binary outcome. In this article, we describe a Stata tool called ARTPEP, which is intended to project the power and events of a. trial with a time-to-event outcome into the future given patient accrual figures so far and assumptions about event rates and other defining parameters. ARTPEP has been designed to work closely with the ART program and has an associated dialog box. We illustrate the use of ARTPEP with data from a phase III trial in esophageal cancer.
引用
收藏
页码:386 / 394
页数:9
相关论文
共 50 条
  • [21] Sample sizes for clinical trials with time-to-event endpoints and competing risks
    Schulgen, G
    Olschewski, M
    Krane, V
    Wanner, C
    Ruf, G
    Schumacher, M
    CONTEMPORARY CLINICAL TRIALS, 2005, 26 (03) : 386 - 396
  • [22] Assessing Clinical Equivalence in Oncology Biosimilar Trials With Time-to-Event Outcomes
    Uno, Hajime
    Schrag, Deborah
    Kim, Dae Hyun
    Tang, Dejun
    Tian, Lu
    Rugo, Hope S.
    Wei, Lee-Jen
    JNCI CANCER SPECTRUM, 2019, 3 (04)
  • [23] A simulation study comparing the power of nine tests of the treatment effect in randomized controlled trials with a time-to-event outcome
    Royston, Patrick
    Parmar, Mahesh K. B.
    TRIALS, 2020, 21 (01)
  • [24] Meta-analysis of clinical trials with competing time-to-event endpoints
    Meddis, Alessandra
    Latouche, Aurelien
    Zhou, Bingqing
    Michiels, Stefan
    Fine, Jason
    BIOMETRICAL JOURNAL, 2020, 62 (03) : 712 - 723
  • [25] Assessing the impact of selection bias on test decisions in trials with a time-to-event outcome
    Ruckbeil, Marcia Viviane
    Hilgers, Ralf-Dieter
    Heussen, Nicole
    STATISTICS IN MEDICINE, 2017, 36 (17) : 2656 - 2668
  • [26] An evaluation of statistical methods for predicting timelines for reaching target number of events in clinical trials with time-to-event endpoints
    Clark, Emma
    Helms, Hans-Joachim
    Stanzel, Sven
    Xia, Fan
    TRIALS, 2017, 18
  • [27] A simulation study comparing the power of nine tests of the treatment effect in randomized controlled trials with a time-to-event outcome
    Patrick Royston
    Mahesh K. B. Parmar
    Trials, 21
  • [28] Review of calculation of conditional power, predictive power and probability of success in clinical trials with continuous, binary and time-to-event endpoints
    Madan G. Kundu
    Sandipan Samanta
    Shoubhik Mondal
    Health Services and Outcomes Research Methodology, 2024, 24 : 14 - 45
  • [29] Review of calculation of conditional power, predictive power and probability of success in clinical trials with continuous, binary and time-to-event endpoints
    Kundu, Madan G.
    Samanta, Sandipan
    Mondal, Shoubhik
    HEALTH SERVICES AND OUTCOMES RESEARCH METHODOLOGY, 2024, 24 (01) : 14 - 45
  • [30] LEVERAGING REAL-WORLD DATA FOR TIME-TO-EVENT ENDPOINTS IN CLINICAL TRIALS
    Parashar, D.
    Almgren, P.
    Berglund, A.
    Guasconi, A.
    Smith, C.
    Torlinska, B.
    Wang, J.
    Wang, Q.
    VALUE IN HEALTH, 2022, 25 (01) : S256 - S256